Gene Delivery Systems: Tailoring Vectors to Reach Specific Tissues by Carlos J. Alméciga-Díaz et al.
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1. Introduction 
The gene therapy concept was developed more than forty years ago. Edward Tatum in a 
historic lecture affirmed: “We can anticipate that viruses will be used effectively for man's benefit, 
in theoretical studies concerning somatic cell genetics and possibly in genetic therapy... We even can 
be somewhat optimistic about the long-range possibility of therapy based on the isolation or design, 
synthesis, and introduction of new genes into defective cells of particular organs”.   Two years later 
Marshall Niremberg predicted that: “in 25 years it would be possible to program the cells with 
synthetic messages”, but called to attention that “it should be postponed until having the sufficient 
wisdom to use this knowledge for the benefit of mankind”. 
Initial efforts to construct vectors were achieved by Rogers and Pfudere in 1968. However, it 
was not until 1990 that the first gene therapy clinical trial was carried-out in a patient with 
adenosine deaminase (ADA) deficiency (Friedmann, 1992). Within the last several years, 
significant advances have been attained in therapies for cancer, AIDS, Parkinson’s disease, X-
linked severe combined immunedeficiency (X-SCID), hemophilias, cystic fibrosis, Leber's 
congenital amaurosi, and β-thalassemia, among others. Nonetheless, an adolescent patient 
suffering from a urea cycle defect died of an anaphylactic reaction a few hours after being 
injected with an adenoviral vector. Soon after, five children participating in a clinical trial to 
correct a X-SCID developed a leukemia-like condition due to the activation of an oncogene 
(Edelstein, 2007). Recently, the tragic death of a volunteer in an clinical trial for rheumatoid 
arthritis using an adenoassociated virus vector was initially associated to a side effect of the 
vector  (Williams, 2007). However, further studies showed that this was caused by an infection 
with Histoplasma capsulatum, which was produced by an immunosuppression condition 
induced for a simultaneous systemic anti-TNF-alpha therapy in the form of the drug 
adalimumab (Williams, 2007). All these failures halted the progress of gene therapy and 
seriously questioned the efficacy of the procedure. It also prompted the need for more basic 
studies on the immunogenic aspects and how to make safer, and more efficient vectors.  
During the last 35 years a long list of viral and non-viral vectors have been developed to 
design a vector that allows gene delivery to specific cell types, has a high gene transfer 
efficiency, produces therapeutic levels of gene expression during long-term periods, and 
minimizes the generation of side effects (Verma & Weitzman, 2005). Although the field has 
made great strides in producing an ideal vector, one of the main challenges remains to aim for 
a cell-specific vector. Most probably a vector left in the general circulation without a specific 
targeting signal, will be sequestered by the liver or may end-up in cells with no need of the 
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transfected gene product. In addition, to date gene therapy still encounters two main 
problems: (i) gene delivery to the central nervous system (CNS), as the gene or its product are 
naturally blocked by the blood brain barrier; and (ii) gene delivery into poorly circulated tissues 
such as bone, where up until now, it has only been achieved with low transfection efficiencies. 
In this chapter, we will explore the modifications carried out in viral and non-viral vectors 
to enhance their natural tropism. Regardless of the vector, modification objectives can be 
summarized in: (i) tropism expansion to permit gene delivery to cells not easily transfected 
with non-modified vector, (ii) cell-type specific transfection reducing side effects, and (iii) 
stealth vector improvement to reduce protein interactions or cells that limit its therapeutic 
activity, e.g. immune system (Yu & Schaffer, 2005).  
2. Retroviral vectors 
Retroviruses are a family of enveloped, diploid, and positive-stranded RNA virus. This family 
is formed by alpharetrovirus, betaretrovirus, deltaretrovirus epsilonretrovirus, 
gammaretrovirus, lentivirus, and spumavirus (foamy virus), from which only the last three 
have been used as gene therapy vectors (Verma & Weitzman, 2005). The genome basically 
consists of three genes: (i) gag, which encodes for viral matrix, capsid and nucleocapsid 
proteins, (ii) pol, which encodes for protease, reverse transcriptase and integrase, and (iii) env, 
which encodes a bipartite membrane-anchored surface (SF) protein (Escors & Breckpot, 2010). 
In addition, complex retroviruses (e.g. lentivirus and foamy virus) have accessory genes for the 
regulation of gene expression, assembly and replication (Escors & Breckpot, 2010).  In the viral 
life cycle, glycoproteins (GPs) play an important role in viral tropism, receptor recognition and 
cell entry (Liang et al., 2009). The binding of the viral GP to the cellular surface protein induces 
a conformational change into the viral GP and leads to fusion and insertion of the capsid into 
the cytoplasm (Yu & Schaffer, 2005). Most of the advantages and limitations of retrovirus 
targeting are related with this cell entry mechanism.  
Retroviral vectors used in gene therapy have properties that allow the transduction of a broad 
array of cells (Cronin et al., 2005; Frecha et al., 2008). However, the use of targeted retroviral 
vectors allowing the delivery of the transgene to cells which are not normally transduced, or 
limiting the delivery to cells which should not be transduced would be advantageous (Cronin 
et al., 2005; Frecha et al., 2008; Lavillette et al., 2001). In general, retroviral targeting can be 
achieved by: (i) engineering the GP to produce a vector that recognizes a specific cell surface 
protein (direct targeting), (ii) pseudotyping with GPs derived from other retrovirus and that 
recognize specific receptors, (iii) using ligands that block the cell entry of the vector to the cells 
expressing the receptor for the ligand, while allow the transduction of others cell types 
(indirect targeting), or (iv) using biospecific antibodies, chemically crosslinking ligands and 
grafting polymers (Fig. 1) (Lavillette et al., 2001; Verhoeyen & Cosset, 2004; Yu & Schaffer, 2005).  
2.1 Retroviral targeting by engineering the glycoproteins 
Direct targeting consists of the insertion of ligands or antibody fragments into the viral GP 
(Fig. 1), which allows recognition of cell surface proteins different from those naturally used 
by the vector (Lavillette et al., 2001).  Direct modification of a GP was first reported in 1990, 
with the successful fusion of CD4 with the GP of a gammaretroviral vector (Young et al., 
1990). Later, a functional murine leukemia virus (MLV) vector bearing a GP protein fused 
with an antibody fragment against a hapten (4-hidroxy-5-iodo-3-nitrophenacetyl caproate) 
demonstrated binding of the modified retroviral vector to hapten, and the ability to package 
a transgene and transduce culture cells (Russell et al., 1993). 
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After these pioneer works revealed the feasibility of GP engineering, different authors studied 
the real potential of this targeting approach. The fusion of the erythropoietin polypeptide with 
the GP of a MLV vector showed for the first time that a chimeric GP was not only correctly 
incorporated into the virus envelope but also allowed the specific transduction of cells 
expressing the EPO receptor (Kasahara et al., 1994). A similar result was reported with a 
gammaretrovirus bearing a GP fused with a single-chain antigen-binding site against a cell 
surface expressed on human carcinoma cells (Kasahara et al., 1994). 
Nevertheless, different studies have exposed the limitations of this approach. The first 
evidence of this limitation was observed with vectors carrying the Ram-1 phosphate 
transporter or the epidermal growth factor (EFG) into the GP, which showed a reduced 
transduction efficiency although the chimeric GPs were correctly expressed, processed, and 
exposed in the viral envelope (Cosset et al., 1995).  A similar observation was reported for a 
gammaretroviral vector with a GP bearing a peptide binding to the αvβ3 integrin (Wu et al., 
2000a), or with the stromal cell derived factor 1-alpha (Katane et al., 2002). These low 
transductions efficiencies were associated with loss or impairment of viral and cell surface 
proteins binding and subsequent membrane fusion and penetration of the viral core into the 
cytosol (Frecha et al., 2008; Lavillette et al., 2001; Yu & Schaffer, 2005). In addition, these 
results strongly suggest that only few set of peptides sequences can be inserted into the GPs 
without altering the mechanism of retrovirus cell entry (Verhoeyen & Cosset, 2004). The 
insertion of spacer sequences between the inserted peptide and the GP has proved to 
overcome this issue, allowing a significant improvement in the transduction efficiency of the 
modified vectors (Kayman et al., 1999).  
2.2 Retroviral targeting by pseudotyping 
Pseudotyping involves the production of viral particles bearing GP derived from other 
enveloped viruses (Fig. 1). This strategy was developed due to the narrow cellular 
transduction profile observed in vectors with native GPs (Cronin et al., 2005; Yu & Schaffer,  
 
 
Fig. 1. Strategies for retroviral targeting. Retroviral vectors can be modified by ligand or 
antibody fraction insertion (engineered glycoproteins), use of glycoprotein (GP) from other 
retrovirus (pseudotyping), or the use of bi-specific antibodies (non-genetic targeting). 
www.intechopen.com
 
Non-Viral Gene Therapy 
 
54
2005). Production of pseudotyped retroviral vectors is a well-established protocol (Bischof & 
Cornetta, 2010), which in most cases is used to allow virus purification, improve the cellular 
transduction, extend the range of transduced cells, and reduce cell toxicity (Cronin et al., 
2005). However, it should be possible to employ natural tropism in GPs used for 
pseudotyping to target vectors bearing these proteins. 
A large set of GPs has been evaluated for vector pseudotyping, among which vesicular 
stomatitis virus glycoprotein (VSV-G) is the most used [reviewed in (Bischof & Cornetta, 
2010; Cronin et al., 2005)]. However, only a few GPs have allowed the transduction of 
different cell types compared to those observed VSV-G pseudotyped vectors. The use of a 
GP derived from rabies virus (RV) for pseudotyping an HIV-1 lentiviral vector allowed the 
transduction of neurons usually non-transduced with VSV-G vectors, since the RV 
glycoprotein induced a retrograde transport along axons (Mazarakis et al., 2001). The 
infusion of an animal model of familial amyotrophic lateral sclerosis (ALS) with a RV-HIV-1 
vector carrying the gene of vascular endothelial growth factor (VEGF) delayed the onset of 
the disease and slowed progression in treated animals. Although treatment was initiated at 
the onset of paralysis CNS tropism of the vector was still significantly improved (Azzouz  
et al., 2004).  
An interesting tropism was also observed for an HIV-1 vector pseudotyped with a GP from 
the lymphocytic choriomeningitis virus (LCMV) (Miletic et al., 2004). In-vitro and in-vivo 
evaluation of a vector pseudotyped with a LCMV GP showed that it transduced, almost 
exclusively, astrocytes; while VSV-G pseudotypes vectors infected neurons as well as 
astrocytes. In addition, LCMV-HIV-1 vector presented a specific transduction of infiltrating 
tumor cells, while VSV-G-HIV-1 vectors transduced mostly normal brain cells in infiltrating 
tumor areas. An HIV-1 vector pseudotyped with an Ebola Zaire virus-derived GP appeared 
useful in the treatment of airway diseases (e.g. cystic fibrosis). This vector allowed in-vitro 
and in-vivo transduction of airway epithelial cells, which was not observed with a VSV-G 
vector (Kobinger et al., 2001). 
A recent modification of this approach used an HIV-1 vector pseudotyped with the GP and 
the fusion protein from a measles virus. The GP had an epidermal growth factor (EGF) or a 
single chain antibody against CD20 (Funke et al., 2008). The CD20-bearing vector was able 
to transduce primary and CD20-positive B cells both alone or within a cell mixture, while a 
VSV-G vector did not transduce these cell types. 
2.3 Indirect retroviral targeting 
This strategy is based on the finding that inclusion of certain peptides into the GP 
significantly impairs transduction of some cells. This prohibits gene delivering into cells that 
should not be transduced and extends viral tropism (Lavillette et al., 2001; Yu & Schaffer, 
2005). First evidence of this approach was discovered while producing a MLV vector 
bearing a GP fused with epidermal growth factor (EGF). Although the chimeric GP was 
correctly expressed and processed, and the modified vector had the ability to bind to the 
EGF receptor, this manipulation completely inhibited vector transduction into cells 
expressing the EGF receptor (Cosset et al., 1995). This transduction inhibition was produced 
because of the modified vector was directed to the late endosome and destroyed by 
lysosomal enzymes.  
A similar result was observed with a vector carrying the stem cell factor (SCF, a c-Kit 
receptor ligand), which selectively inhibited vector transduction on c-Kit-expressing cells 
(Fielding et al., 1998). When a mixture of EGF receptor-positive cancer cells and c-Kit-
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positive hematopoietic cells were exposed to the above mentioned vectors, cancer cells were 
selectively transduced by the SCF-displaying vector, whereas hematopoietic cells were 
selectively transduced by the EGF-displaying vector. In-vivo proof-of-concept of this 
strategy was established after intravenous infusion of an EGF-displaying HIV-1 vector, 
showing preferable transduction of spleen with very low levels on EGF-receptor rich tissues 
(e.g. liver). Furthermore, the VSV-G vector transduced heart, skeletal muscle, lung, brain, 
kidney, ovaries and bone-marrow (Peng et al., 2001). Transduction inhibition of human and 
canine cells was also observed for a spleen necrosis virus bearing EFG, which was restored 
after cleavage via factor Xa at a site located between EFG and GP (Merten et al., 2003). 
A variant of this strategy takes advantage of protease-activatable gene delivery vehicles. 
Matrix metalloproteinases (MMPs) are commonly overexpressed in angiogenesis, 
inflammation, and cancer invasion. The inclusion of a MMPs-cleavable peptide within an 
EGF-retroviral vector permitted that in the presence of exogenous MMPs, the infectivity of 
the MMP-EGF vector but not of the EGF-vector, could be restored. This MMPss-sensitive 
vector could efficiently discriminate between two different cell types, infecting only MMP-
positive cells (Peng et al., 1997). 
2.4 Non-genetic retroviral targeting 
This strategy involves the use of antibodies or adapter molecules bound to the GP (Fig. 1) 
(Lavillette et al., 2001; Yu & Schaffer, 2005). This was the first approach used for cell 
targeting of a gammaretrovirus by using two biotinilated antibodies bridged by 
streptavidin: one against a GP and the other one against a specific cell membrane marker 
(Roux et al., 1989). This strategy allowed the specific transduction of cells expressing class I 
or II major histocompatibility complex (MHC) molecules by using monoclonal antibodies 
against these MHC molecules and against GP from the retroviral vector (Roux et al., 1989).  
For targeting of a retroviral vector to folate receptor-expressing epidermoid carcinoma cells, 
a myeloproliferative sarcoma retrovirus was modified with folic acid (Reddy et al., 2001). 
Although receptor binding was observed, this vector was not able to induce gene 
expression. Similar results were observed for a MLV vector bearing a single chain anti-folate 
receptor antibody to produce vectors targeting ovarian cancer cells (Pizzato et al., 2001), 
manifesting the limitations of folate receptor targeting. A modification of this approach 
combines genetic modification of the GP by inclusion of an IgG-binding domain and the 
conjugation with an antibody that reacts with specific cell surface molecules expressing the 
antigen (Ohno et al., 1997). By changing the monoclonal antibody it was possible to 
transduce efficiently and specifically a variety of cell lines. The potential of this approach 
was confirmed by in-vivo evaluation of modified vectors conjugated with antibodies against 
surface proteins expressed in cancer cells, indicating that after intravenous infusion the 
vector preferentially transduced these cells (Liang et al., 2009). This strategy has been used 
both with gammaretroviral and lentiviral vectors. It represents a powerful tool that can be 
easily modified to obtain a site-specific gene expression for the treatment of cancers, genetic, 
infectious and immune diseases. 
3. Adenoviral vectors 
An adenovirus (AdV) is a non-enveloped virus formed by an icosahedral protein capsid 
surrounding a lineal double-stranded DNA of 36 kb (Douglas, 2007). The AdV capsid is 
characterized by the presence of 252 different capsomers and long fibers protruding from 
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each of the twelve vertices. Seven polypeptides form this complex capsid: hexon  
(II), penton base (III), fiber (IV), IIIa, VI, VIII, and IX (Campos & Barry, 2007; Sharma et al., 
2009). The cell receptor depends on the virus subgroup: A, E and F subgroups use the cell 
surface coxsackievirus B and adenovirus receptor (CAR); B1 and B2 subgroups use  
CD46, CD80/86, receptor X, or heparan sulfate proteoglycan (HSPG); C subgroup uses 
CAR, HSPG, MHC-I, vascular cell adhesion molecule-I (VCAM-I), or integrins; and D 
subgroup uses CAR, sialic acid, or CD46 (Arnberg, 2009; Campos & Barry, 2007; Sharma 
et al., 2009). 
Adenoviral vectors have been used as tools for gene therapy since the late 80s (Friedmann, 
1992), and the first clinical trial was started in 1993 (Douglas, 2007). Since then, over 392 
clinical trials using AdV vectors have been carried out. Currently AdV are the most used 
vectors for gene therapy and represent 24% of clinical trials total (Edelstein, 2007). In 
addition, the first commercially approved gene therapy product, Gendicine, is based on an 
AdV vector engineered to express p53 for treatment of patients with head and neck 
squamous cell carcinoma (Peng, 2005).  
AdV vectors are mainly derived from serotypes 2 (AdV2) and 5 (AdV5). They have the 
advantage of inducing high levels of gene expression, are able to infect both diving and non-
dividing cells, and can be purified to high titers. Furthermore, AdV2 and AdV5 have high 
bloodstream stability with a reduced risk of insertional mutagenesis, since their genome 
remains extrachromosomal (Douglas, 2007; Edelstein, 2007; Volpers & Kochanek, 2004). 
Nonetheless, several drawbacks have been identified during in-vivo evaluation of these 
vectors: (i) presence of pre-existing antibodies that rapidly neutralize the vector, (ii) after 
intravenous administration the vector is mainly taken up by liver cells, limiting the vector to 
reach its target tissue in adequate concentrations, and (iii) use of high doses in an effort to 
overcome these problems has not proven to be an adequate and safe approach (Arnberg, 
2009). Three strategies can be used to solve these issues: (i) use of vectors from other 
subgroups different from AdV2 and AdV5 (subgroup C), (ii) use of non-human serotypes, 
and (iii) retargeting of the vector to cells or tissues of interest (Arnberg, 2009). In this section 
we will explore different strategies for AdV retargeting that include genetic modification of 
the capsid, use of molecular adaptors and chemical modification of the capsid (Fig. 2) 
(Campos & Barry, 2007). 
3.1 Genetic modification of the AdV capsid 
Genetic modification of the viral capsid involves incorporation of foreign peptides into 
exposed regions of the capsid. In this manner the gene encoding for the peptide is inserted 
into the vector’s genome (Fig. 2) (Campos & Barry, 2007). The possibility of altering the AdV 
vector capsid was first evaluated by the insertion of octapeptides into the hexon (Crompton 
et al., 1994) or the fiber knob (Krasnykh et al., 1998). This established the possibility of 
producing viable vectors with foreign proteins present on the vector capsid surface. Further 
experiments revealed the possibility of expanding the vector tropism by inserting a heparin-
binding domain (Wickham et al., 1996), or an Arg-Gly-Asp (RGD)-containing peptide into 
the fiber knob (Dmitriev et al., 1998).  
Although different studies indicated the feasibility to target vectors to specific cell types, 
genetic modification often resulted in failure to rescue viable viruses, or in an impaired 
virus packing, peptide exposure, and vector transduction (Leissner et al., 2001; Wu et al., 
2005). Because the insertion of a pre-selected peptide into a fiber knob often fails to generate 
an adenovirus vector, use of random peptide libraries displayed directly on the AdV capsid 
allows isolation of viable vectors with high affinity for specific tissues or cells (Miura et al.,  
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Fig. 2. Strategies for Adenoviral vectors targeting. Adv vectors can be modified by ligand or 
antibody fraction insertion (genetic modification), use of bi-specific antibodies (molecular 
adaptors), or conjugation with polymers bearing or not a ligand (chemical modification). 
2007). A similar approach involves the pre-selection of peptides by using a phage display 
peptide library, from which peptides with high affinity for a certain cell type are selected 
and then inserted into the AdV vector capsid. This has allowed the targeting of AdV vectors 
to epithelium cells (Nicklin et al., 2001b), tumor cells (Rittner et al., 2007), and neurons 
(Schmidt et al., 2007). 
Most efforts to modify the AdV vector capsid have been on vector targeting to tumor cells 
(Bachtarzi et al., 2008). Some examples of this approach include: (i) production of an AdV 
vector bearing a CAR protein fused with EGF producing an enhanced gene transfer efficiency 
in pancreatic carcinoma cells (Wesseling et al., 2001); (ii) a vector with a polylysine motif in the 
fiber for a CAR-independent binding to HSPG for specific transduction of different breast 
cancer cells (Ranki et al., 2007); and (iii) vectors with high affinity for prostate adenocarcinoma 
(Wu et al., 2010), and human colon carcinoma cells (Rittner et al., 2007).  
In addition to cancer cell, genetically modified AdV vectors have been used as tools for gene 
delivery to other cell types. The insertion of an RGD-modified AdV allowed the production 
of a vector that mediated cell entry via RGD binding to integrins. Administration into the 
synovial lining improved the outcome of gene therapy for arthritis (Bakker et al., 2001). 
Targeting to endothelial cells, an important target in vascular gene therapy, was possible 
after insertion of the SIGYPLP peptide into the fiber protein in combination with fiber 
mutations that block natural CAR binding (detargeting) (Nicklin et al., 2001b). For specific 
kidney gene delivery, the intravenous administration of HTTHREP- and HITSLLS-bearing 
AdV vectors resulted in selective renal targeting, specifically of tubular epithelium and 
glomeruli (Denby et al., 2007). 
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Although genetically modified AdV vectors have been widely studied, most of these 
modifications have been carried out only into fiber or hexo. Recently it was determined that 
protein IX in the capsid is a viable platform for the insertion of single-chain variable-
fragment antibodies (scFv) or single-domain antibodies (sdAb) for AdV vector retargeting. 
Even so, only sbAb enhanced virus infection of cells expressing the targeted receptor. Thus, 
proving that the nature of the ligand can significantly affect vector targeting as already had 
been observed with fiber and hexo (Poulin et al., 2010). 
3.2 Molecular adaptors for AdV targeting 
Although genetic modification is the most direct form of vector targeting it has the 
disadvantage of not all peptides can be inserted into the vector capsid. An approach to 
overcome this difficulty is to use molecular adaptors consisting of a capsid-binding domain 
fused with a cell-binding domain (Fig. 2) (Campos & Barry, 2007). This strategy has the 
advantages of not requiring a correct processing of the cell-binding peptide, since it is not 
translated with the viral capsid proteins; and that virtually any cell-binding peptide can be 
fused with the capsid. 
The primary adaptor molecules are bi-specific antibodies against a capsid protein and a 
cellular receptor. The use of a single-chain bi-specific antibody directed against human 
EGFR and fiber knob significantly increased gene transfer into primary glioma cells and 
organotypic glioma spheroids, while reducing natural tropism dramatically (Grill et al., 
2001). The human epithelial cell adhesion molecule (EpCAM) is highly expressed in 
malignant lesions of the stomach and esophagus. By using bi-specific antibodies against 
adenovirus fiber knob protein and EpCAM a specific transduction of gastric and esophageal 
cancer cell lines was observed with reduced transduction in normal cells (Heideman et al., 
2001). For other epithelial tumors, e.g. colon, lung and breast, it was possible to target 
vectors by using a bi-specific adapter protein, which fused the ectodomain of CAR with a 
single-chain anti-carcinoembryonic antigen (CEA) antibody. This adaptor molecule allowed 
the targeting of AdV vectors to CEA-positive epithelial tumor cells in cell culture, in 
subcutaneous tumor grafts, and in hepatic tumor grafts (Li et al., 2007). A similar strategy 
was used for vector targeting to pancreatic carcinoma cells by using a vector bearing an EGF 
peptide fused with CAR (Wesseling et al., 2001). The combination of this adaptor molecule 
with the insertion of an RGD-containing peptide into the fiber knob resulted in a significant 
enhancement of gene transfer. 
3.3 Chemical modification of the AdV capsid 
The third strategy for AdV targeting is the chemical modification of the viral capsid by 
using primary-amine reactive groups (Fig. 2) (Campos & Barry, 2007). The capsid 
modification with polyethylene glycol (PEG - PEGylation) is a promising strategy to 
diminish vector toxicity and immune response. Although other polymers have also been 
used PEGylation can be employed to modify tropism. Polymer-coated vectors can be 
targeted to specific cells by incorporation onto the polymer molecules that bind to specific 
cell-surface proteins (Campos & Barry, 2007; Volpers & Kochanek, 2004). 
PEG-modified AdV vectors were conjugated with an anti-HER2/neu monoclonal antibody 
leading to an enhanced and specific transduction of HER2/neu over-expressed breast cancer 
cells. Furthermore, a significant reduction of the innate immune response against the vector 
was accomplished (Jung et al., 2007; Kim et al., 2011). Conjugation of PEG-AdV vectors with 
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an RGD peptide led to a specific αvβ3 integrin vector cell entry. This resulted in a significant 
improvement in transduction and specificity of gene delivery into endothelial cells. These 
events have implications on the treatment of rheumatoid arthritis, inflammatory bowel 
disease and epithelial tumors (Eto et al., 2005; Ogawara et al., 2006). Transduction of bone 
marrow derived human mesenchymal stem cells (MSC) can be significantly improved by 
using a PEGylated AdV conjugated with a blocked poly-L-lysine. However, modification on 
vector tropism was not clearly reported in this study (Park et al., 2010).  
Although a great part of systemically administrated vector particles is scavenged by Kupffer 
cells in the liver, the use of a PEG- or a dextran-coated vectors allowed the specific 
transduction of hepatocytes independent of the presence of Kupffer cells, emphasizing the 
potential for therapeutic liver-directed gene transfer (Prill et al., 2010). Similar result can be 
observed by using a multivalent hydrophilic polymer based on poly-[N-(2-
hydroxypropyl)methacrylamide] conjugated with EGF or VCAM, producing a CAR-
independent binding and uptake into EGF- or VCAM-positive target cells selectively in 
mixed culture and also in xenografts in-vivo (Fisher et al., 2001). 
4. Adeno-associated viral vectors 
Adeno-associated virus (AAV) are non-enveloped virus belonging to the Parvoviridae family 
that need a helper virus, such as AdV or herpes simplex, for efficient infection and 
replication (Flotte, 2004). AAV are formed by a single-stranded DNA genome of 4.7 kb that 
contains two open reading frames (ORFs): (i) rep, which encodes for proteins Rep78, Rep68, 
Rep52 and Rep40, involved in virus genome replication, packing and integration; and (ii) 
cap, which encodes for the capsid proteins VP1, VP2 and VP3 (Wu et al., 2006). These ORFs 
are flanked by two Inverted Terminal Repeats (ITRs), involved in complementary DNA 
synthesis, Rep binding proteins, and site-specific genome integration in human chromosome 
19 (Wu et al., 2006). 
AAV capsid is formed by 60 subunits of VP1, VP2 and VP3 in a 1:1:10 ratio (Michelfelder & 
Trepel, 2009). These proteins share the C-terminal sequence, while the N-terminal sequences 
differ according to the start codon, being VP1>VP2>VP3 (Wu et al., 2006). Capsid structure 
has been elucidated for AAV2, AAV3, AAV4, AAV8 and AAV9 serotypes (Govindasamy et 
al., 2006; Lerch et al., 2010; Mitchell et al., 2009; Nam et al., 2007; Xie et al., 2002). The 
difference within capsid proteins allows for each serotype to use a specific receptor: (i) 
AAV2 and AAV3 use the HSPG, (ii) AAV1, 4 and 5 use glycans with sialic acid ends, and 
(iii) AAV8 uses the 37/67 kDa laminin receptor (Nam et al., 2007; Summerford & Samulski, 
1998; Wu et al., 2006). AAV can infect a wide number of tissues including liver, lung, central 
nervous system, muscle, and heart; although as a result of the differences in receptor used, 
each serotype has a characteristic tropism (Flotte, 2004; Verma & Weitzman, 2005). 
From the first clinical trial for cystic fibrosis patients with AAV vectors in 1995, over 75 
clinical trials have been conducted. Pathologies such as α1-antitrypsin deficiency, 
Alzheimer’s disease, Canavan’s disease, hemophilia B, Leber congenital amaurosis, 
Parkinson’s disease and muscular dystrophy; have attained promising results and no direct 
side effects have been associated with the vector (Warrington & Herzog, 2006). Although 
AAV vectors have shown to be promising tools for therapeutic gene delivery, they cannot 
transduce all cell types and could be useful to restrict its transduction to specific cell types. 
Strategies to modify the natural tropism of AAV vectors include: (i) the insertion of ligands 
into the viral capsid, (ii) use of chimeric or mosaic capsids, and (iii) conjugation with ligands 
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through non-genetic modifications (Fig. 3) (Choi et al., 2005; Kwon & Schaffer, 2008; 
Michelfelder & Trepel, 2009). 
 
 
Fig. 3. Strategies for AAV vectors retargeting. AAV vectors can be modified by insertion of 
ligands into the capsid’s proteins (ligand insertion), mixing capsid proteins from different 
serotypes (mosaic or chimeric capsids), or absorption of molecules onto the capsid using bi-
specific antibodies or ligands fused with molecular bridges (non-genetic modification). 
4.1 Targeting by ligand insertion 
Mutagenesis analysis have permitted the identification of positions within the viral capsid 
that allow peptide insertion with little or no effect on DNA packaging and virus trafficking. 
For AAV2-derived vectors, peptides inserted in positions 1, 34, 138, 161, 459, 584, 587 and 
588 (relative to VP1 start codon) are displayed on the vector surface, and allow production 
of vectors with similar viral titers to those observed for unmodified AAV2 vectors (Shi et al., 
2001; Wu et al., 2000b). Most of the studies have used positions 138 (VP2 N-terminal), 587 
and 588 (HSPG binding domain) to insert peptides ranging from 5 to 272 amino acids (Loiler 
et al., 2003; Michelfelder et al., 2009; Nicklin et al., 2001a; Perabo et al., 2006; Shi et al., 2001; 
White et al., 2007; White et al., 2004; Wu et al., 2000b; Yu et al., 2009). Capsid protein 
modifications have improved gene delivery to lung (Kwon & Schaffer, 2008), endothelial 
cells (Nicklin et al., 2001a), pancreatic islets (Loiler et al., 2003), vascular tissue (White et al., 
2004), atherosclerotic lesions (White et al., 2007), muscle (Yu et al., 2009), myocardium (Yang 
et al., 2009), and cancer cells (Michelfelder et al., 2009). 
Although the therapeutic effect of these vectors still remains to be seen, there is a long list of 
reports showing different advantages of peptide insertion within different positions of the 
viral capsid. Insertion after position 588 provided a complete AAV2 retargeting with inhibition 
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of binding to HSPG (Büning et al., 2003; Perabo et al., 2006). AAV vectors designed for 
vascular tissue targeting were constructed by insertion after position 587 of peptides 
MSLTTPPAVARP and MTPFPTSNEANL, which showed increased transduction and 
specificity for venous endothelial cells and reduction of hepatocytes transduction (White et al., 
2004). In-vivo experiments with these modified AAV vectors demostrated a reduction in liver 
and kidney transduction, while a significantly higher and specific targeting towards vena cava 
cells was observed (White et al., 2004). Recently, two new peptides (CAPGPSKSC and 
CNHRYMQMC) were evaluated for AAV retargeting to atherosclerotic lesions (White et al., 
2007). The modified vectors showed higher levels of in vitro transduction than those observed 
for the untagged vector in human, murine, and rat endothelial cells. In vivo experiments 
showed that substantial higher levels of both peptide-modified AAV2 vectors were detected in 
the brachiocephalic artery (the site of advanced atherosclerotic plaques) and aorta, whereas 
reduced levels of modified vector were detected in all other organs examined (White et al., 2007). 
Serpin receptor ligand inserted after position 138 increased by 15-fold the transduction of 
vector on a lung epithelial cell line expressing the serpin receptor (Wu et al., 2000b). 
Insertion of a peptide that binds to the luteinizing hormone receptor after position 139 
allowed production of a modified vector able to specifically transduce ovarian cancer cells (a 
luteinizing hormone receptor-bearing cell line) in an HSPG-independent manner (Shi et al., 
2001). Insertion after position 138 of the 28-amino acid ApoE-derived ligand led to a 90-fold 
increase in pancreatic islet cells in-vitro transduction. Additionally, a four-fold increase of 
human antitrypsin expression was observed compared to unmodified AAV vector 
transduction (Loiler et al., 2003). Viral dose can be reduced 100-fold with similar 
transduction results as a consequence of ApoE-derived ligand insertion with a critical 
impact on side effect reduction. Functional AAV-modified vectors with long peptides up to 
30 kDa have been reported, yet a laborious producing protocol is necessary to increase yield 
(Warrington et al., 2004).  
Although these studies have demonstrated the feasibility of AAV retargeting, there is only 
one study evaluating the therapeutic effect of a modified AAV vector. In the study, AAV 
vectors were designed for brain-endothelial targeting, using peptides identified by phage 
display (Chen et al., 2009). After intravenous administration of modified vectors in MPS VII 
mice, there was extensive expression of enzyme in brain, leading to correction of lysosomal 
storage and reversal of established behavioral deficits (Chen et al., 2009). 
During the last years we have worked in the development of a gene therapy strategy for the 
Mucopolysaccharidosis IV A (Morquio A disease) by using AAV vectors (Alméciga-Díaz et al., 
2010; Alméciga-Díaz et al., 2009; Gutierrez et al., 2008). Morquio A disease, as well as other 
mucopolysaccharidosis, has a marked bone involvement, and an effective therapy should 
focus on the treatment in these manifestations. Recently, we designed a bone-targeting AAV 
vector bearing an aspartic acid octapeptide inserted immediately after the N-terminal of the 
VP2 capsid protein. The vector was designed to interact with hydroxyapatite (HA), a main 
component of bone (Tomatsu et al., 2010). We observed that the unmodified AAV vector had 
low bone affinity, while the bone-targeting vector had significantly higher HA affinity with up 
to 36.6-fold higher vector genome copies in cortical bone compared with the unmodified 
vector matrix (Alméciga-Díaz CJ, Montaño A, Barrera L, Tomatsu S., unpublished data). 
4.2 Chimeric or mosaic capsids 
A mosaic capsid AAV is a virion that is composed of a mixture of viral capsid proteins from 
different serotypes, which are mixed during viral assembly. On the other hand, a chimeric 
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capsid AAV is a vector produced by the insertion of a sequence from another wild-type 
AAV into the ORF of the capsid gene (Fig. 3) (Choi et al., 2005; Michelfelder & Trepel, 2009). 
AAV vectors produced by the mixture of capsid proteins of AAV serotypes 1 to 5 led to 
high-titer viral particles with mixtures of serotype 1, 2, or 3; whereas intermediate titers 
were observed from AAV5 mixtures (Rabinowitz et al., 2004). Transduction levels varied 
depending on capsid mixture, producing a synergistic effect in transduction when AAV1 
capsids were combined with AAV2 or AAV3 (Rabinowitz et al., 2004). Similar results were 
observed for a vector produced by the mixture of AAV1 and AAV2 capsid proteins, which 
exhibited similar titers to those observed for native vectors. The biodistribution profile 
combined transduction characteristics of both parent vectors (i.e. muscle and liver 
transduction) (Hauck et al., 2003). 
A variant of this strategy uses capsid proteins bearing foreign peptides mixed with wild-
type capsids. An AAV2 vector containing wild-type and immunoglobulin-binding Z34C 
fragment of protein A-bearing capsid proteins; made possible the production of a vector 
with high virus particle and transduction titers, and the capacity to transduce selectively 
and efficiently MO7e (human megakaryoblastic leukemia cell line) and Jurkat cells (T 
lymphocyte cells line) (Gigout et al., 2005). A mosaic vector produced by the mixture of 
wild-type and integrin-targeted capsid proteins resulted in a vector with a 50 - 100-fold 
enhancement in endothelial cell gene transfer. This is higher compared to the vector 
produced only with integrin-targeted capsid (Stachler & Bartlett, 2006). 
4.3 Adsorption of receptor ligands 
This strategy involves the binding of molecules onto the viral capsid to alter natural 
tropism of AAV vectors (Fig. 3). Initial approaches used bi-specific antibodies consisting 
of an anti-AAV antibody cross-linked with another antibody that binds specifically to a 
cellular receptor (Choi et al., 2005). In the first approach, an anti-AAV antibody was 
chemically cross-linked to Fab arms of the αIIβ3 integrin binding monoclonal AP-2 
antibody, allowing the specific transduction of megakaryocyte cells expressing the 
integrin (Ponnazhagan et al., 1996). 
In a second approach, a high-affinity biotin-avidin interaction was used as a molecular 
bridge for the adsorption of streptavidin-fused ligands (Ponnazhagan et al., 2002). This 
strategy did not affect virus production and allowed the vector to be specifically targeted to 
EGFR- or fibroblast growth factor receptor (FGFR)-positive cells after conjugation of EGF or 
FGF onto the biotinilated capsid. Recently the exogenous glycation of the viral capsid was 
presented as a potential alternative to redirect vectors from liver to skeletal and cardiac 
muscle after systemic administration in mice (Horowitz et al., 2011). 
5. Non-viral vectors 
Non-viral vectors for gene delivery offer several advantages over viral vectors, since these 
include lack of an immune response, simple synthesis, and low scale-up production cost 
(Niidome & Huang, 2002). Non-viral vectors may include lipoplexes (DNA-liposome 
complex), polyplexes (DNA-polymer complex), lipopolyplexes (DNA-liposome-polymer 
complex) and peptide-based complexes (Douglas, 2008); which can be mixed with physical 
methods (e.g. electroporation, ultrasound, gene gun or hydrodynamic infusion) to improve 
the gene delivery (Niidome & Huang, 2002). In addition, most used non-viral vectors do not 
integrate into the host genome reducing the risk of mutagenic events in the transfected cells 
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(Kim et al., 2010). However, transduction efficiencies are significantly lower than that of 
viral vectors (Douglas, 2008). The reader is referred to other chapters in this book edition for 
more thorough treatises of non-viral vectors. 
Although some physical methods allow gene delivery to a specific cell type, we will only 
consider some strategies developed to modify vector tropism. It is important to note that 
although most of these studies have been evaluated exclusively in-vitro, they constitute 
proof-of-concept. 
5.1 Lipoplexes 
Lipoplexes are the result of a complex formation between cationic liposomes (artificial 
closed vesicles of lipid bilayer membranes) and genetic material. They can be considered a 
synthetic means of encapsulating genetic material until it reaches its cellular target (Tros et 
al., 2010). The main strategies for targeting of lipoplexes involve use of chelator lipids that 
bind metal-bearing ligands, or the modification with polymers bearing a ligand (Fig. 4). 
The insertion of the chelator lipid 3 (nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) 
in a lipoplex preparation allowed the engraftment of a His-tagged vascular epidermal 
growth factor (VEGF) ligand and specific transfection of cells expressing the VEGF receptor 
(Fig. 4) (Herringson et al., 2009). A similar approach was used to target small iRNAs to B 
lymphocytes by using a lipoplex bearing the NTA(3)-DTDA chelator lipid engrafted with a 
His-tagged CD4 or to cells expressing the receptor for tumor necrosis factor alpha (TNFα) 
by engrafting with a His-tagged TNFα ligand (Herringson & Altin, 2009).  
 
 
Fig. 4. Modification of lipoplexes and polyplexes. Ligands can be bound to non-viral vectors 
through direct binding, spacer (polymer)-mediated binding, or chelator lipid-mediated 
binding (ligand should be fused with a metal). 
To improve hepatic specific delivery of a lipoplex after systemic administration, PEG 
molecules were added to the complex and galactose molecules were covalently affixed at the 
distal end of the PEG chain to allow an active targeting to the asialoglycoprotein-receptor 
present on hepatocytes. This resulted in an 18-fold increase in hepatic gene expression 
(Morille et al., 2009). Inclusion of a PEG conjugated with a nuclear localization signal (NLS) 
and added to a lipoplex preparation permitted transfection of endothelial cells in the 
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presence of serum. This method was used as a model for transfection of blood-brain barrier 
cells considered difficult targets for non-modified viral and non-viral vectors (Zhang et al., 
2009). A similar strategy was used for targeting of a lipoplex to tumor cells expressing the 
tumor-associated glycoprotein (TAG)-72 (Kim et al., 2008). In this work, a Fab' fragment 
from an anti-TAG-72 monoclonal antibody was conjugated with PEG and included within 
the lipoplex, providing specific gene delivery to TAG-expressing tumor cells both in-vitro 
and in-vivo, while non-targeted lipoploxes did not produce the transfection of those cells.      
Ligands can be also directly conjugated with liposome molecules (Fig. 4). A hyaluronic acid-
liposome conjugate resulted in an increased gene delivery to breast cancer cells with high 
CD44 levels. Conversely, cells with low CD44 levels were not transfected (Surace et al., 
2009). Conjugation of the peptide 4-fluorobenzoyl-RR-(L-3-(2-naphthyl)alanine)-CYEK-(L-
citrulline)-PYR-(L-citrulline)-CR with a liposome permitted targeting of a lipoplex to 
CXCR4-expressing cells, with transfection efficiency depending upon CXCR4 expression 
levels (Driessen et al., 2008). Conjugation of a liposome with transferrin presented a 
significant increment in iRNA delivery to hepatocarcinoma cells, with reduced toxicity and 
enhanced specific gene silencing compared to non-modified lipoplexes (Cardoso et al., 
2007). Transferin-conjugated lipoplexes were also used to evaluate specific gene delivery to 
a metastatic mammary carcinoma cell line, although the results did not demonstrate a 
significant increase in cytotoxicity with modified lipoplexes in comparison with non-
modified lipoplex (Lopez-Barcons et al., 2005). 
Another strategy based on ex-vivo gene therapy assessed the challenge of nuclear entry by 
using plasmids transfected with a cationic lipid vector in MSC (Hoare et al., 2010). To 
enhance gene expression in MSC, they used NLS peptides to direct the plasmid to the 
nucleus. A significant increase was observed in reporter gene delivery compared to non-
modified plasmid. They also noticed the lipid had a protective impact on the plasmid-NLS 
complex. Differentiation potential was not affected by NLS peptides.  
5.2 Polyplexes 
Polyplexes are non-viral vectors formed by genetic material coupled with cationic polymers 
including polylysine (PLL), polyarginine, PEG, polyethylenimine (PEI), polyamidoamine 
(PAMAM), dendrimers, and chitosan. The mechanism involves interaction between 
negatively charged DNA or iRNA molecules with positively charged molecules within the 
polymer (Tros et al., 2010). To target polyplexes to specific cells, they can be modified by 
incorporation of ligands as small molecules, vitamins, carbohydrates, peptides, or proteins 
(Wagner et al., 2005). 
PEG-derived vectors are widely used as gene therapy tools as a result of their well-known 
capacity to enhance gene delivery and induce a longer DNA half-life time (Midoux et al., 
2008). Due to the possibility to bind ligands in the terminal ends of the polymer (Fig. 4), 
PEG-derived vectors are commonly used for cell specific gene delivery using non-viral 
vectors (Hughes & Rao, 2005). PEG polyplexes have been conjugated with a transferrin 
peptide to target vectors to receptor-expressing cells in two prostate cancer cell lines (Nie et 
al., 2011). In addition they have been conjugated with EGFR ligand or lactose for specific 
transfection of human hepatocarcinoma cell lines (Klutz et al., 2011; Oishi et al., 2007).  
PEG has also been used as a spacer to bind ligands to polyplexex (Fig. 4), although it has 
been associated in some cases with reduced transfection efficiencies. A complex of DNA and 
the HIV-derived TAT protein (which has important translocation abilities due to its strong 
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cell surface adherence) was conjugated with an ICAM-1 ligand by using a PEG spacer 
allowing an efficient and specific transfection of ICAM-1 expressing cells (Khondee et al., 
2011). Similarly, a PEI-derived polyplex was engineered for enhanced and specific delivery 
of VEGF iRNA in prostate cancer cells. The conjugation with prostate cancer-binding 
peptide via a PEG spacer, showed a significantly higher VEGF inhibition than with the 
unmodified PEI polyplex in human prostate carcinoma cells (Kim et al., 2009). Anionic 
liposomes and cationic polymers do not display an efficient targeting to liver or tumors 
cells. Thus, a lipopolyplex was constructed with a liposome. A PEI polymer and a PEG 
polymer bearing a monoclonal antibody permitted an in-vitro and in-vivo transfection of 
tumor cells (Hu et al., 2010). A similar strategy was used to target an iRNA to tumor cells 
expressing the EGFR by using this lipopolyplex bearing the EGFR ligand (Hu et al., 2011). 
Direct binding of ligands in other polyplexes has also been evaluated. Conjugation of folic 
acid with the aminomethacrylate-phosphoryl-choline based copolymer, allowed transfection 
of cells overexpressing the receptor for folic acid in some human tumors cells (Lam et al., 
2009). A PEI-derived polyplex conjugated with an Arg-Gly-Asp peptide, which binds to the 
αvβ3 integrin receptor, resulted in efficient transfection of HeLa cells with low and high 
densities of αvβ3 integrin (Ng et al., 2009). As observed in viral vectors and lipoplexes, 
antibodies can be also conjugated with polyplexes to target genetic material to specific cell 
types. A successful overexpression of the human epidermal growth factor receptor-2 (HER2) 
by transfection with a polyplex conjugated with an anti-HER2 monoclonal antibody has 
been reported for a breast cancer cell line (Chiu et al., 2004). Another approach in adult 
MSCs used a modification of a PLL polymer with a palmitic acid substitution to target bone 
marrow stromal cells. A transfection efficiency similar to that of adenoviral vectors was 
obtained, opening the possibly to efficiently transfecting these cells without the side-effects 
and cell toxicity observed with viral vectors (Incani et al., 2007). 
In-vivo evaluations of these modified polyplexes include use of a PEI-derived complex 
bearing an FGFR ligand for transfection of tumor cell lines. It demonstrated in-vitro and in-
vivo specific transduction of tumor cells overexpressing the FGFR (Li & Huang, 2006), and 
the use of a poly[N-(2-hydroxypropyl)methacrylamide]-derived polyplex modified with an 
anti-P-selectin antibody. In-vivo specific and enhanced gene delivery to inflamed cremasteric 
venules was observed (Newman et al., 2009). A significant retargeting to tumor cells was 
also observed with a PEI polyplex carrying an antibody against a tumor-specific protein via 
a PEG spacer, with low expression in non-tumor cells (Duan et al., 2010).  
6. Conclusions 
Modification of gene therapy vectors for specific cell type gene delivery can have a 
significant impact on vector tropism limitations, side effects, and consolidation of gene 
therapy as a viable treatment. Vector modifications can be grouped in three basic strategies 
regardless of vector type: genetic modification (ligand insertion within the capsid), chemical 
modification (polymers or ligand cross-linking), or the use of adaptor molecules (bi-specific 
antibodies). Most studies have focused on vector design and proof-of-concept of specific 
gene delivery, while only few of them have evaluated the therapeutic impact of these 
modifications. In that sense, future studies should focus on assessing the potential of these 
modified vectors to improve gene therapy trials in an effort to advance from the bench 
science to the clinic trials. Special attention should be placed in the development of modified 
vectors for gene delivery to CNS and bone. Since, under normal conditions they show a 
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limited transfection profile with the currently available vectors. Finally, parallel research 
should be carried out in tissue-specific promoters to design safer integrating vectors, reduce 
immune response, and improve the processes of vector production.   
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